Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Careers
  • Newsroom
Company Announcement
06 January 2023

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory...
Inside information
22 December 2022

Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®

U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023FDA has completed review of Alvotech’s...
Company Announcement
16 December 2022

Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT

Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds. The aggregate principal amount is approximately US$70 million,...
Company Announcement
16 December 2022

Alvotech Completes $59.7 Million Private Placement

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of...
Company Announcement
08 December 2022

Alvotech Shares Start Trading on Nasdaq Iceland Main Market

Listing on the Main Market can increase visibility, which may allow the company to appear in both domestic and global indexesAlvotech became first dual-listed Icelandic company in the U.S. and Iceland...
Company Announcement
07 December 2022

Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe

Hukyndra® (adalimumab) launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe Follows...
Company Announcement
06 December 2022

Alvotech publishes prospectus related to the admission to trading and listing on Nasdaq Iceland Main Market

Reference is made to the announcement issued on December 2, 2022 confirming that Nasdaq Iceland has approved Alvotech S.A’s (“Alvotech”) request for admission to trading of its shares on the Nasdaq Iceland Main Market (“Main Market”), pending passporting of the prospectus to Iceland.
Company Announcement
02 December 2022

Nasdaq Iceland Approves the Request for Trading of Alvotech’s Shares on the Main Market

Nasdaq Iceland has approved Alvotech S.A’s (“Alvotech”) request for admission to trading of its shares on the Nasdaq Iceland Main Market (“Main Market”). Alvotech’s shares will be admitted to trading...
Company Announcement
01 December 2022

Alvotech: Restricted share unit agreements

Alvotech Société anonyme Registered office: 9, rue de Bitbourg, L-1273 Luxembourg R.C.S. Luxembourg: B258884
Company Announcement
01 December 2022

Alvotech Announces Changes to its Leadership Team

Hafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating Officer Mark Levick has decided to step down as Chief Executive Officer and Robert...
1…2425…33
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.